Stevanato Group Earnings Reports

Stevanato Group reported a 9% increase in revenue for the first quarter of 2025, reaching €256.6 million, primarily driven by strong performance in the Biopharmaceutical and Diagnostic Solutions segment. Gross profit and operating profit margins also improved. The company maintained its full-year revenue guidance but lowered its adjusted EBITDA and adjusted diluted EPS guidance to reflect the estimated impact of recently announced tariffs.

Stevanato Group reported Q4 2024 revenue of €330.6 million, a 3% increase year-over-year. The Biopharmaceutical and Diagnostic Solutions segment grew 7%, offsetting a 16% decline in the Engineering segment. Gross profit margin declined to 29.7%, impacted by vial destocking, while operating profit margin improved to 20.2%. Adjusted EPS was €0.19, reflecting cost management initiatives and strong performance in high-value solutions.